Prevalence and risk f actors influencing the development of arterial hypertension in patients with a gout

Background. Cardiovascular diseases (CVD) is the leading cause of death for gout. Arterial hypertension is a proven CVD risk factor (CVD-RF).

Objective. To assess the factors influencing on development of an arterial hypertension in patients with a gout. Subjects and methods. 286 male patients fulfilling Wallace proposed criteria for gout were included in the study: age 51.2 [42.8; 59.4] years, disease duration - 6.2 [3.8; 12.1] years, number of joints involved during disease course - 7 [4; 12], subcutaneous tophi - in 35% of patients, intraosseous tophi - in 44%, nephrolithiasis - in 69%, abdominal obesity - in 71%. All patients underwent standard clinical examination, C-reactive protein (CRP), total cholesterol, triglycerides, low and high density lipoproteins, serum uric acid, serum creatinine, smoking, family history of arterial hypertension, body mass index (BMI), diabetes mellitus was performed by standard procedure. We estimated the adjusted odds ratio (OR) and 95% confidence interval (95% CI).

Results. There were two groups of patients with arterial hypertension diagnosed on clinical data: group 1 (with arterial hypertension) - 244 (85%) patients, group 2 (without arterial hypertension) - 42 (15%) patients. The group 1 patients were older (52.3 [44.5; 61.1] vs 41.9 [38.3; 50.1] years old), had longer duration of gout (6.7 [3.9; 13.7] vs 4.5 [3; 7.9]), a higher number of joints involved during disease course (8 [4; 12] vs 5 [3; 9]). The frequency of family history of arterial hypertension (68.3 vs 48.8%), abdominal obesity (55.3 vs 33.3%), nephrolithiasis (71 vs 54.7%), intraosseous tophi (48 vs 21%) was higher in group 1 as compared with group 2, р<0,05. BMI and CRP level was higher in group 1 compared with group 2: 30.2 [27.4; 33.1] vs 27.9 [26.3; 30.5] kg/m², and 12.7 [5.84; 19.2] vs 7.8 [3.7; 16.4] mg/l, respectively, p<0.05. We did not find differences of lipid profile, serum uric acid, and serum creatinine level in groups 1 and 2. We also did not find differences the frequency of smoking, diabetes mellitus, subcutaneous tophi in both groups.

Abdominal obesity (OR - 1.247; 95% CI: 1.063-1.462), family history of arterial hypertension (OR - 2.8; 95% CI: 1.5-5.4), disease duration more than 10 years (OR - 4.5; 95% CI: 1.1-19.4), intraosseous tophi (OR - 3.0; 95% CI: 1.4-6.4), increased the risk for arterial hypertension in patients with a gout.

Conclusion. The majority (85%) of patients with gout had arterial hypertension. Abdominal obesity, family history of arterial hypertension, disease duration more than 10 years, intraosseous tophi were associated with an increased risk of arterial hypertension in patients with a gout.

1. Luk AJ, Simkin PA. Epidemiology of hyperuricemia and gout. Am J Manag Care. 2005;11(15 Suppl):S435-442; quiz S465-468.

2. Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther. 2006;8(Suppl 1):S2. DOI: 10.1186/ar1907

3. Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: Prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11(11):649-662. DOI: 10.1038/nrrheum.2015.91

4. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med. 2012;125(7):679-687.e1. DOI: 10.1016/j.amjmed.2011.09.033

5. Nyberg F, Horne L, Morlock R, et al. Comorbidity burden in trial-aligned patients with established gout in Germany, UK, US, and France: A retrospective analysis. Adv Ther. 2016;33(7):1180-1198. DOI: 10.1007/s12325-016-0346-1

6. Wandell P, Carlsson AC., Ljunggren G. Gout and its comorbidities in the total population of Stockholm. Preventive Medicine. 2015;81:387-391. DOI: 10.1016/j.ypmed.2015.10.003

7. Rho YH, Lu N, Peloquin CE, et al. Independent impact of gout on the risk of diabetes mellitus among women and men: a population-based, BMI-matched cohort study. Ann Rheum Dis. 2016;75(1):91-95. DOI: 10.1136/annrheumdis-2014-205827

8. Kuo CF, Yu KH, See LC, et al. Risk of myocardial infarction among patients with gout: a nationwide population-based study. Rheumatology (Oxford). 2013;52 (1):111-117. DOI: 10.1093/rheumatology/kes169

9. Wun YT, Chan KCC, Lee A. Comorbidity in general practice. Fam Pract. 1998;15(3):266-268. DOI: 10.1093/fampra/15.3.266

10. Krishnan E, Kwoh CK, Schumacher HR, et al. Hyperuricemia and Incidence of hypertension among men without metabolic syndrome. Hypertension. 2007;49(2):298-303. DOI: 10.1161/01.HYP.0000254480.64564.b6

11. Sundstrom J, Sullivan L, D’Agostino RB, et al. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence in the Framingham Heart Study. Hypertension. 2005;45(1):28-33. DOI: 10.1161/01.HYP.0000150784.92944.9a

12. Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2011;63(1):102-110. DOI: 10.1002/acr.20344

13. Feig DI, Johnson RJ. Hyperuricemia in childhood essential hypertension. Hypertension. 2003;42(3):247-252. DOI: 10.1161/01.HYP.0000085858.66548.59

14. Arnold B, Alper Jr, Wei Chen, et al. Childhood uric acid predicts adult blood pressure: The Bogalusa heart study. Hypertension. 2005;45(1):34-38. DOI: 10.1161/01.HYP.0000150783.79172.bb

15. Mazzali M, John Kanellis, Lin Han, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressureindependent mechanism. Am J Physiol Renal Physiol. 2002;282(6):991-997. DOI: 10.1152/ajprenal.00283.2001

16. Watanabe S, Kang DH, Feng L, et al. Uric acid, hominoid evolution and the pathogenesis of salt-sensitivity. Hypertension. 2002;40(3):355-360. DOI: 10.1161/01.hyp.0000028589.66335.aa

17. Mazzali M, Kim YG, Suga S, et al. Hyperuricemia exacerbates chronic cyclosporine nephropathy. Transplantation. 2001;71(7):900-905. DOI: 10.1097/00007890-200104150-00014

18. Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005;67(5):1739-1742. DOI: 10.1111/j.1523-1755.2005.00273.x

19. Zhou Y, Fang L, Jiang L, et al. Uric acid induces renal inflammation via activating tubular NF-kB signaling pathway. PLoS One. 2012;7(6):e39738. DOI: 10.1371/journal.pone.0039738

20. Tausche AK, Christoph M, Forkmann M, et al. As compared to allopurinol, uratelowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout. Rheumatol Int. 2014;34(1):101-109. DOI: 10.1007/s00296-013-2857-2

21. Gunawardhana L, McLean L, Punzi HA, et al. Effect of febuxostat on ambulatory blood pressure in subjects with hyperuricemia and hypertension: A phase 2 randomized placebo-controlled study. J Am Heart Assoc. 2017;6(11):e006683. DOI: 10.1161/jaha.117.006683

22. Doehner W, Schoene N, Rauchhaus M, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation. 2002;105(22):2619-2624. DOI: 10.1161/01.cir.0000017502.58595.ed

23. Dopp JM, Philippi NR, Marcus NJ, et al. Xanthine oxidase inhibition attenuates endothelial dysfunction caused by chronic intermittent hypoxia in rats. Respiration. 2011;82(5):458-467. DOI: 10.1159/000329341

24. Johnson RJ, Choi H, Yeo AE, Lipsky PE. Pegloticase treatment significantly decreases blood pressure in patients with chronic gout. Hypertension. 2019;74(1):95-101. DOI: 10.1161/HYPERTENSIONAHA.119.12727

25. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104. DOI: 10.1093/eurheartj/ehy339

26. Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of gout. Arthritis Rheum. 1977;20(3):895-900. DOI: 10.1002/art.1780200320

27. Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999-3058. DOI: 10.1093/eurheartj/ehw272

28. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice. The Sixth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016;252:207-274. DOI: 10.1714/2729.27821

29. Richette P, Doherty M, Pascual E, et al. 2016 Updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42. DOI: 10.1136/annrheumdis-2016-209707

30. Kuo C F, Grainge MJ, Mallen C, et al. Comorbidities in patients with gout prior to and following diagnosis: Case-control study. Ann Rheum Dis. 2016;75(1):210-217. DOI: 10.1136/annrheum-dis-2014-206410

31. Feig DI, Kang DH, Nakagawa T, et al. Uric acid and hypertension. Curr Hypertens Rep. 2006;8(2):111-115. DOI: 10.1007/s11906-006-0005-z

32. Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med. 2005;165(7):742-748. DOI: 10.1001/archinte.165.7.742

33. McAdams-DeMarco MA, Maynard JW, Baer AN, Coresh J. Hypertension and the risk of incident gout in a population-based study: the atherosclerosis risk in communities cohort. J Clin Hypertens (Greenwich). 2012;14(10):675-679. DOI: 10.1111/j.1751-7176.2012.00674.x

34. Pan A, Teng GG, Yuan JM, Koh WP. Bidirectional association between self-reported hypertension and gout: The Singapore Chinese Health Study. PLoS One. 2015;10(10):e0141749. DOI: 10.1371/journal.pone.0141749

35. Johnson RJ, Rodriguez-Iturbe B, Kang DH, et al. A unifying pathway for essential hypertension. Am J Hypertens. 2005(3);18:431-440. DOI: 10.1016/j.amjhyper.2004.08.035

36. Johnson RJ, Herrera-Acosta J, Schreiner GF, Rodriguez-Iturbe B. Subtle acquired renal injury as a mechanism of saltsensitive hypertension. N Engl J Med. 2002;346(12):913-923. DOI: 10.1056/NEJMra011078

37. Friedl HP, Till GO, Trentz O, et al. Role of oxygen radicals in tourniquet related ischemia reperfusion injury of human patients. Klin Wochenschr. 1991;69(21-23):1109-1112. DOI: 10.1007/BF01645168

38. Saito I, Saruta T, Kondo K, et al. Serum uric acid and the reninangiotensin system in hypertension. J Am Geriat Soc. 1978;26(6):241-247. DOI: 10.1111/j.1532-5415.1978.tb02396.x

39. Schumacher HR Jr. Crystal-induced arthritis: An overview. Am J Med. 1996;100(2A):46S-52S. DOI: 10.1016/s0002-9343(97)89546-0

40. Barskova VG, Il’inykh EV, Eliseev MS, Zilov AV, Nasonov EL. Cardiovascular risk in patients with gout. Obesity and metabolism. 2006;3(8):40-44 (In Russ.).

41. Perez-Ruiz F, Martinez-Indart L, Carmona L, et al. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis. 2014;73(1):177-182. DOI: 10.1136/annrheumdis-2012-202421

42. Chow CK, Teo KK, Rangarajan S, et al. PURE Study Investigators. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310(9):959-968. DOI: 10.1001/jama.2013.184182

43. Roughley MJ, Belcher J, Mallen CD, Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Res Ther. 2015;17(1):90. DOI: 10.1186/s13075-015-0610-9

44. Yu KH, Kuo CF, Luo SF, et al. Risk of end-stage renal disease associated with gout: a nationwide population study. Arthritis Res Ther. 2012;14(2):R83. DOI: 10.1186/ar3806

45. Jing J, Kielstein JT, Schultheiss UT, et al. Prevalence and correlates of gout in a large cohort of patients with chronic kidney disease: the German Chronic Kidney Disease (GCKD) study. Nephrol Dial Transplant. 2015;30(4):613-621. DOI: 10.1093/ndt/gfu352

46. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937-952. DOI: 10.1016/S0140-6736(04)17018-9

47. Iljina AE, Barskova VG, Nasonov EL. Gout, hyperuricemia and cardiovascular risk. Nauchnoprakticheskaya revmatologiya = Rheumatology Science and Practice. 2009;47(1):56-62 (In Russ.). DOI: 10.14412/19954484-2009-143

48. Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: The Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007;57(1):109-115. DOI: 10.1002/art.22466

49. Richette P, Clerson P, Perissin L, et al. Revisiting comorbidities in gout: A cluster analysis. Ann Rheum Dis. 2015;74(1):142-147. DOI: 10.1136/annrheumdis-2013-203779

50. Fagard R, Brguljan J, Staessen J, et al. Heritability of conventional and ambulatory blood pressures. A study in twins. Hypertension. 1995;26(6 Pt 1):919-924. doi: 10.1161/01.hyp.26.6.919.

51. Luft FC. Twins in cardiovascular genetic research. Hypertension. 2001;37(2 Pt 2):350-356. DOI: 10.1161/01.hyp.37.2.350

52. Parsa A, Brown E, Weir MR, et al. Genotype-based changes in serum uric acid affect blood pressure. Kidney Int. 2012;81(5):502-507. DOI: 10.1038/ki.2011.414

53. Mallamaci F, Testa A, Leonardis D, et al. A polymorphism in the major gene regulating serum uric acid associates with clinic SBP and the white-coat effect in a family-based study. J Hypertens. 2014;32(8):1621-1628. DOI: 10.1097/HJH.0000000000000224

54. Palmer TM, Nordestgaard BG, Benn M, et al. Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts. BMJ. 2013;347:f4262. DOI: 10.1136/bmj.f4262

55. Sedaghat S, Pazoki R, Uitterlinden AG, et al. Association of uric acid genetic risk score with blood pressure: the Rotterdam study. Hypertension. 2014;64(5):1061-1066. DOI: 10.1161/HYPERTENSIONAHA.114.03757

56. Stack AG, Hanley A, Casserly LF, et al. Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. QJM. 2013;106(7):647-658. DOI: 10.1093/qjmed/hct083

57. Keenan T, Zhao W, Rasheed A, et al. Causal assessment of serum urate levels in cardiometabolic diseases through a Mendelian randomization study. J Am Coll Cardiol. 2016;67(4):407-416. DOI: 10.1016/j.jacc.2015.10.086